trial

Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia

NCTId NCT00409201
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Unknown
Enrollment 30
Sponsored by Abarbanel Mental Health Center
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Unknown
Enrollment
30
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Double
Start
2006-03
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
reboxetine adjuvant therapy

Sponsors

Abarbanel Mental Health CenterLead Sponsor

Investigators

1
stanislav baranchik, mdPrincipal Investigator

Sites

2 total
Bat Yam, IsraelBat Yam, Israel

Facts & assertions

3 sourced
Enrollment
30
Phase
PHASE1
Status
UNKNOWN
relationships
The graph out of here
drug
reboxetine adjuvant therapy
drug
lead_sponsor
Abarbanel Mental Health Center
company
indication
Schizophrenia
indication
Behavior
indication
Schizophrenia
indication
investigator
stanislav baranchik, md
person